Article - 18/11/2019

Researchers successfully rejuvenate the immune system in animal models

It is well known that stem cells age. Even the human immune system loses its power with age. Since all immune cells are derived from blood-forming stem cells, it is quite natural to associate the weakening of the immune system (immune senescence) with the ageing of blood-forming stem cells. Stem cell researchers and immunologists from the University of Ulm have now demonstrated the important role that blood-forming cells play in the ageing of the…

The newborn's immune system is suddenly confronted with microorganisms, food and numerous environmental influences at birth. How do the baby's immune cells prepare for this moment during pregnancy and birth? How do external influences shape the immune system immediately after birth? And what influence does an event like a premature birth have?

Development of anti-tumour agents - 20/03/2023

Targeting the protective shield of cancers

Cancer cells have different mechanisms to help them escape destruction by the immune system. Solid tumours, for example, are often surrounded by a protective layer of lactate, which has a strong immunosuppressive effect. WMT AG from Heidelberg is developing small drug molecules that reduce lactate production and thus make cancer cells vulnerable to immune system attacks.

Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB - 24/04/2020

A rapid pyrogen test: the human immune system as model

Every year, around 11 million people die of sepsis (blood poisoning) caused by microorganisms or microbial residues, known as pyrogens, entering the bloodstream. The smallest amounts can trigger fever. Researchers from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart have developed a pyrogen test that does not require a laboratory and is not tested on animals. It is expected to be placed on the market soon.

Inhibition of a protein complex in cells of the immune system prevents rejection of transplanted organs – this has been shown in a study by immunologists from the University of Konstanz, the Biotechnology Institute Thurgau (BITg) and Chongqing Cancer University Hospital.

Affimed GmbH - 01/07/2020

"Innate cell engager" fighting against cancer

In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.

Article - 29/04/2021

Nanobodies for determining neutralising antibodies after corona infection

After contact with a pathogen, ideally our immune system generates neutralising antibodies to prevent a future infection. With NeutrobodyPlex, scientists from Reutlingen and Tübingen have developed a highly specific test procedure based on single-domain antibodies (nanobodies) that can be used to easily and reliably determine the quality of the immune response against the novel coronavirus.

Dossier - 09/09/2013

New trends in the field of immunology

B- and T- lymphocytes along with macrophages have long been regarded as the most important cells of the human immune system and have been a major focus of research. This has now changed and it is now the dendritic cells that are regarded as the major components of the adaptive immune system. Research into innate immune defence mechanisms has become more important due to the discovery of the role of Toll-like receptors as first-line of defence.

Dossier - 13/04/2015

Boosting the immune system can improve cancer prevention and treatment

The activation of the body’s immune system to fight cancer is not only a promising therapeutic concept, but is already used in medical practice. The first immunotherapies have been approved and many more are either in the experimental stages or already undergoing clinical testing. Vaccines to prevent certain types of cancer are already being used successfully around the world.

The development of immunotherapies against blood cancer could be more successful if T cells are activated moderately rather than excessively. Scientists from the German Cancer Research Center have now been able to show this in mice: If the researchers blocked a cytokine that slows down the immune system, the T cells became exhausted and failed in the fight against leukemia.

Intestinal peptide heals lung - 14/10/2020

Inhalation of intestinal hormone VIP helps against immunotherapy-induced pneumonia

If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.

Researchers at the Faculty of Medicine of the University of Freiburg discover key factor in the development of immune cells. New approaches for the treatment of ALPS.

A cutting-edge chemical process is the first to make it possible to quickly and easily produce modified peptides with boronic acids. As part of this work, scientists managed to synthesize a large number of different biologically active peptide boronic acids and investigate their properties. They open up new possibilities in the young research field of synthetic immunology and could go on to be used primarily in immunotherapy.

Researchers from Freiburg and Harvard publish the three-dimensional structure of the B cell antigen receptor, shedding new light on its composition.

Bacteria of the species Pseudomonas aeruginosa are antibiotic-resistant hospital germs that can enter blood, lungs and other tissues through wounds and cause life-threatening infections. In a joint project, researchers from the Universities of Freiburg and Strasbourg in France have discovered a mechanism that likely contributes to the severity of P. aeruginosa infections.

Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors.

Dossier - 16/12/2021

Advanced therapy medicinal products: gene and cell therapies

Novel gene and cell therapies for treating incurable and hereditary diseases have raised high expectations. However, success has so far been limited to the long-established bone marrow transplants involving the administration of haematopoietic stem cells used to treat blood cancer. CAR T-cell therapies have recently emerged as a major new hope in cancer treatment.

Article - 17/02/2021

Whole blood model enables development of early warning system for sepsis

Sepsis is a life-threatening disease that can be treated all the more successfully the faster therapy is initiated. It is not just the infection itself that is so dangerous, but a dysregulated response of the immune system. Physicians at Ulm University Hospital have now developed an animal-free test system that can be used to research the disease and develop innovative diagnostic tools to quickly assess a patient's sepsis risk and optimise…

Predicting the success of cancer treatment - 20/06/2023

Focusing on gut microbiome for CAR T-cell therapy

Cancer immunotherapies use the body's own defences to fight tumour cells. An international consortium of researchers from Germany and the USA led by the DKFZ in Heidelberg has demonstrated that the effectiveness of CAR T-cell therapies greatly depends on the composition of the gut microbiome. The researchers have also developed a model for predicting the long-term response to the treatment.

Article - 10/06/2021

New study: vaccine therapy for treating patients with chronic leukaemia

Personalised peptide vaccination is expected to improve the treatment of patients with chronic lymphocytic leukaemia. A research team from Tübingen has started a Phase I clinical trial with CLL patients who will undergo ibrutinib treatment. Other leukaemia sufferers as well as cancer patients in general are also expected to benefit in the long term.

Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.

Signal mechanisms in inflammatory processes - 18/05/2021

Newly discovered substances activate the inflammasome in macrophages

Low-grade chronic inflammation caused by components of the innate immune system may increase the risk of developing a variety of diseases in the long term. In their search for the signalling mechanisms underlying these inflammatory processes, Prof. Dr. Olaf Groß' research group at the Freiburg University Medical Centre discovered new active substances with immunostimulatory properties that may open up additional possibilities in cancer…

Inflammation of the heart muscle, also known as myocarditis, is a serious consequence of a viral infection. This can impede the heart’s ability to pump blood in the long term. In a current study, researchers of the Faculty of Medicine of the University of Freiburg have discovered a new approach for treating myocarditis.

In a so-called inactivated or killed vaccine, the virus particles it contains are first rendered inactive by means of the toxic chemical formaldehyde. A better way of achieving this, however, is to irradiate the pathogens with low-energy electrons. Four Fraunhofer Institutes have now developed a new method of vaccine production based on this technique that is not only quicker but also guarantees a higher quality of product.